Brenton Hanlon was named VP of North American medical sales and marketing for Abaxis (Union City, California). Hanlon, a member of the Abaxis board since 1996, has resigned his position on the board to assume this management/operational position within the company. Most recently, Hanlon was president/CEO of Hitachi Chemical Diagnostics. Abaxis makes point-of-care blood analysis instruments for the medical and veterinary markets.

The American College of Chest Physicians (Northbrook, Illinois) has named Paul Markowski, as the executive VP/CEO for the international medical specialty society. For the last 4 years, Markowski has been the deputy executive VP/COO at the American Academy of Otolaryngology Head and Neck Surgery. The mission of the ACCP is to promote the prevention and treatment of diseases of the chest through leadership, education, research, and communication.

Greg Fischer was named senior VP of sales and marketing for AvMed (Miami). Most recently, Fischer was VP of sales and marketing for Blue Cross & Blue Shield (BCBS) of South Carolina. AvMed is a not-for-profit health plan, and is solely focused on providing health coverage to Florida citizens and businesses.

• Blue Shield of California (San Francisco) reported the promotion of Mark Gastineau to senior VP of Blue Shield of California's Individual, Small Group, and Government Business Unit (ISGBU). Gastineau joined Blue Shield in 2006 as VP of ISGBU finance and underwriting. Blue Shield of California is an independent member of the Blue Shield Association, a not-for-profit health plan dedicated to providing Californians with access to high quality care at a reasonable price.

• BioTime (Alameda, California) said that Walter Funk, PhD, has joined its management team as VP for stem cell research. Most recently, Funk co-founded Parallax Venture Partners and Phyllom. BioTime is focused on regenerative medicine and blood plasma volume expanders.

Dave Clennell was named director of quality of DxS (Manchester, UK). Previously, Clennell was international director of quality for Lombard Medical Technologies. DxS is a personalized medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients.

• GeNOsys (Provo, Utah) reported that Clark Mower has resigned as chairman and a director of the company. John Miller, the company's CEO and founder, was named by the board to succeed Mower. GeNOsys is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems.

James Deal was named to the board of MedCath (Charlotte, North Carolina). Since 2006, Deal has been CEO of Hospice Compassus. MedCath is a healthcare provider focused on high acuity healthcare services, predominately the diagnosis and treatment of cardiovascular disease

• PLUS Diagnostics (Lakewood, New Jersey) has named Mohammad Kamal, MD, to chief medical officer and Mark Machulcz to executive VP of operations. Kamal is an assistant clinical professor of pathology at UCLA. Machulcz previously directed pan-India operations for a unit of Quest Diagnostics. PLUS Diagnostics is an anatomic pathology company.